Cavli Wireless Is Set to Unveil the Next Generation of LPWAN-based IoT with C42GM Smart Cellular IoT Module at Embedded World 2022, Germany.
17.6.2022 13:31:00 EEST | Business Wire | Press release
Cavli Wireless will participate in the Embedded World 2022 edition in Nuremberg, Germany, from June 21-23, 2022. The Embedded World event is the world's biggest trade fair for everything Embedded, from electronic systems, distributed intelligence, the Internet of Things, e-mobility, energy efficiency, and much more. The company will be exhibiting its IoT connectivity solutions in hall 5, booth no: 5-362.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220617005168/en/
Powering the next generation of LPWAN IoT with Cavli C42GM Smart Cellular IoT Module (Graphic: Business Wire)
The premier showcase at the Cavli booth will be the new launch of the C42GM LTE CAT M1/NB1/NB2 compatible Smart Cellular IoT Module, which can be deployed across the globe, making it an ideal solution for logistics, automotive, vehicle tracking systems, and more.
C42GM is a dual-mode LTE CAT M1/NB1/NB2 (upgradable to Release 14) compatible Smart Cellular Module, based on 3GPP Release 13, that comes with an integrated eSIM. C42GM has a battery life profile of ten years due to Deep Sleep Mode capability. It also comes with integrated GNSS and Sigfox radio capability that can equip OEMs to explore use cases that need the hybrid LPWAN approach. As John Mathew, Chief Technology Architect at Cavli Wireless, quoted, “the integrated eSIM coupled with pre-loaded global connectivity further cements the C42GM as the world's most powerful LPWAN-based cellular IoT module."
By virtue of the Hubble Stack Intelligence, C42GM can be managed via Hubble Lens, an advanced remote diagnosis feature of the Cavli Hubble IoT Management platform wherein a customer or a Cavli Support Engineer can remotely diagnose, monitor & debug the field device with zero physical intervention, thereby paving the way for the true scaling of IoT.
Due to Cavli’s strong operator partnerships in the EU, we have an extensive footprint across Europe for our local LTE as well LTE-M connectivity offering, which is unparalleled in the industry in terms of service quality & pricing.
Join Cavli Wireless on June 22 at 16:00 GMT and participate in the exhibitor's forum where Thomas Fesquet, Business Engagement Manager for Cavli Wireless will be unveiling C42GM for our European customers & technology partners visiting the Embedded World event. Watch this video by Cavli Wireless for more information https://www.youtube.com/watch?v=DfyRiYjpkdM
"The Embedded World 2022 event is the premier trade fair for technology companies from around the globe to present their flagship offerings," said Tarun Thomas George, Chief Operating Officer at Cavli Wireless. "We are beyond excited to be a part of this prestigious event, share the stage alongside industry heavyweights, and demonstrate to the world how Cavli Wireless is democratizing the Internet of Things."
About Cavli Wireless
Cavli Wireless designs and manufactures industrial-grade cellular IoT smart modules that improve equipment reliability and expedite development processes for various applications. Cavli's smart cellular modules are equipped with global cellular connectivity through integrated eSIM functionality that provides users affordable international data pricing, simplified device management, and centralized subscription management through the proprietary cloud-based platform Cavli Hubble.
About Embedded World
Every year, the Embedded World Exhibition & Conference in Nuremberg offers the embedded community the opportunity to learn about innovations, exchange ideas, and maintain and establish valuable contacts. Exhibitors present state-of-the-art on all facets of embedded technologies, from components, modules, and complete systems to operating systems and software, hardware and software tools, and services related to embedded systems.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220617005168/en/
Contact information
Ajit Thomas, CMO, Cavli Wireless Inc
ajit@cavliwireless.com
+1-650-535-1150
https://www.cavliwireless.com/
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom